Increasing access will require addressing the significant barriers to care, such as treatment cost, site of care, and the policies that insurance plans can implement, such as step therapy and prior authorizations. For the study, the team used national insurance claims data for more than 97,000 commercially insured US adults diagnosed with obesity, but not diabetes, between June 2021 and July 2022
1 These data come from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 300 million patient records from 1,800 hospitals and more than 41,000 clinics from all 50 U.S
What happens if I stop taking GLP-1s
When compared to GLP1RAs, which improve insulin sensitivity primarily through weight reduction, a post-doc regression analysis of HOMA2-IR indicates that only 2030% of the improvement in insulin sensitization observed with tirzepatide is due to weight loss (NCT03951753) [77, 78]
Comparing Research Grade vs
